Design and early clinical evaluation of selective inhibitors of monoamine oxidase

The Pharmacological Basis of Therapeutics

1986 • 2,365 citations

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

1984 • 1,007 citations

Pargyline Prevents MPTP-Induced Parkinsonism in Primates

1984 • 575 citations

Simultaneous Determination of 3,4‐Dihydroxyphenylalanine, 5‐Hydroxytryptophan, Dopamine, 4‐Hydroxy‐3‐Methoxyphenylalanine, Norepinephrine, 3,4‐Dihydroxyphenylacetic Acid, Homovanillic Acid, Serotonin, and 5‐Hydroxyindoleacetic Acid in Rat Cerebrospinal Fluid and Brain by High‐Performance Liquid Chromatography with Electrochemical Detection

1982 • 350 citations

HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS

1963 • 329 citations

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys

1984 • 323 citations

Polymers for Sustained Macromolecule Release: Procedures to Fabricate Reproducible Delivery Systems and Control Release Kinetics

1980 • 254 citations

Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships

1985 • 129 citations

Monoamine Oxidase Inhibitors

2016 • 88 citations

Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action.

1984 • 84 citations

Recent observations on the clinical pharmacology of (-)deprenyl

1978 • 74 citations

(E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase

1984 • 56 citations

Design of enzyme inhibitors as drugs

1989 • 52 citations

Inhibition of Monoamine Oxidase Selectively in Brain Monoamine Nerves Using the Bioprecursor (E‐β‐Fluoromethylene‐m‐Tyrosine (MDL 72394), a Substrate for Aromatic L‐Amino Acid Decarboxylase

1985 • 47 citations

Dosage form Design for Improvement of Bioavailability of Levodopa II: Bioavailability of Marketed Levodopa Preparations in Dogs and Parkinsonian Patients

1980 • 44 citations

Monoamine Oxidase Inhibitors

1983 • 41 citations

MDL 72145, an Enzyme‐Activated Irreversible Inhibitor with Selectivity for Monoamine Oxidase Type B

1984 • 40 citations

The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties ofl-deprenyl and MDL 72145

1985 • 36 citations

Simultaneous assay of 3,4-dihydroxyphenylethylene glycol and norepinephrine in human plasma by high-performance liquid chromatography with electrochemical detection

1985 • 31 citations

In vitro and in vivo effects of α-acetylenic dopa and α-vinyl dopa on aromatic l-amino acid decar☐ylase

1979 • 23 citations

Depression of Sympathetic Nervous Function by DL-α-Monofluoromethyldopa, an Enzyme-Activated, Irreversible Inhibitor of L-Aromatic Amino Acid Decarboxylase

1980 • 21 citations

Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase

1983 • 20 citations

Dual enzyme-activated irreversible inhibition of monoamine oxidase

1986 • 17 citations

Measurement of tyramine in human plasma, utilising ion-pair extraction and high-performance liquid chromatography with amperometric detection

1984 • 13 citations

(-)Deprenyl — the MAO inhibitor without the ‘cheese effect’

1979 • 12 citations

Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B

1986 • 10 citations